Brentuximab vedotin - CD30 positive systemic anaplastic large cell lymphoma Initial PBS authority application Supporting information form (PB123)

You must lodge this form for a patient starting initial Pharmaceutical Benefits Scheme (PBS) subsidised treatment with brentuximab vedolin.

 

Page last updated: 5 February 2016

This information was printed Saturday 1 October 2016 from humanservices.gov.au/health-professionals/forms/pb123 It may not include all of the relevant information on this topic. Please consider any relevant site notices at humanservices.gov.au/siteinformation when using this material.